HARVARD BIOSCIENCE INC
For the period ended Sep 30, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 8, 2024
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
HARVARD BIOSCIENCE, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited, in thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at June 30, 2024 | 43,611 | $436 | $234,905 | $(153,226) | $(14,868) | $67,247 |
| Stock option exercises | 6 | - | 15 | - | - | 15 |
| Stock-based compensation | - | - | 1,053 | - | - | 1,053 |
| Net loss | - | - | - | (4,802) | - | (4,802) |
| Other comprehensive income | - | - | - | - | 1,809 | 1,809 |
| Balance at September 30, 2024 | 43,617 | $436 | $235,973 | $(158,028) | $(13,059) | $65,322 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at June 30, 2023 | 42,688 | $457 | $231,533 | $(142,548) | $(14,054) | $75,388 |
| Stock-based compensation | - | - | 1,363 | - | - | 1,363 |
| Net loss | - | - | - | (1,239) | - | (1,239) |
| Other comprehensive loss | - | - | - | - | (1,226) | (1,226) |
| Balance at September 30, 2023 | 42,688 | $457 | $232,896 | $(143,787) | $(15,280) | $74,286 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at December 31, 2023 | 43,395 | $434 | $232,435 | $(145,605) | $(14,190) | $73,074 |
| Stock option exercises | 14 | - | 43 | - | - | 43 |
| Stock purchase plan | 72 | 1 | 175 | - | - | 176 |
| Vesting of restricted stock units | 150 | 1 | - | - | - | 1 |
| Shares withheld for taxes | (14) | - | (59) | - | - | (59) |
| Stock-based compensation | - | - | 3,379 | - | - | 3,379 |
| Net loss | - | - | - | (12,423) | - | (12,423) |
| Other comprehensive income | - | - | - | - | 1,131 | 1,131 |
| Balance at September 30, 2024 | 43,617 | $436 | $235,973 | $(158,028) | $(13,059) | $65,322 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at December 31, 2022 | 42,082 | $454 | $229,008 | $(142,190) | $(15,052) | $72,220 |
| Stock option exercises | 214 | 3 | 506 | - | - | 509 |
| Stock purchase plan | 91 | - | 215 | - | - | 215 |
| Vesting of restricted stock units | 413 | - | - | - | - | - |
| Shares withheld for taxes | (112) | - | (451) | - | - | (451) |
| Stock-based compensation | - | - | 3,618 | - | - | 3,618 |
| Net loss | - | - | - | (1,597) | - | (1,597) |
| Other comprehensive loss | - | - | - | - | (228) | (228) |
| Balance at September 30, 2023 | 42,688 | $457 | $232,896 | $(143,787) | $(15,280) | $74,286 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.